Transcription

1 natomic Pathology / OSTEOPONTIN IN MESOTHELIL PROLIFERTIONS Immunohistochemical Expression of Osteopontin in Epithelioid Mesotheliomas and Reactive Mesothelial Proliferations Dean-Yar Tigrani, MD, and Jamie. Weydert, MD Key Words: Osteopontin; Mesothelioma; Immunohistochemistry DOI: /ME4VG11LDX8KMTN bstract The morphologic distinction of epithelioid mesothelioma from a reactive mesothelial proliferation can be difficult. Recent studies have demonstrated that serum osteopontin levels are increased in patients with mesotheliomas. We sought to determine if osteopontin expression is diagnostically helpful in distinguishing epithelioid mesothelioma from reactive mesothelial proliferations. We studied 7 cases of epithelioid mesothelioma and 20 cases of reactive mesothelial proliferations by immunohistochemical analysis using standard technique. ll 7 mesotheliomas and 19 of 20 reactive mesothelial proliferations showed osteopontin expression. Osteopontin expression is not restricted to malignant mesothelial proliferations, and immunohistochemical analysis for osteopontin is not helpful in determining reactive vs malignant mesothelial proliferations. The reported usefulness of osteopontin as a serum tumor marker for mesothelioma may be due to differences in the amount or character of secreted protein in malignant mesothelioma compared with reactive mesothelial proliferations. Malignant mesothelioma is a tumor of mesothelial cell origin, which lines serosal surfaces such as the pleural, peritoneal, pericardial, and testicular cavities. Pleural malignant mesotheliomas are strongly associated with previous asbestos exposure. The prognosis for pleural malignant mesotheliomas is poor, with a median survival of less than 12 months after diagnosis. 1,2 Tissue pathology remains the gold standard of diagnosis of mesothelioma. The grave prognosis and medicolegal issues that are engendered by a diagnosis of malignant mesothelioma place pathologists in a critical and often difficult position as a clinical diagnostician. The differentiation of mesothelioma from carcinoma of nonmesothelial origin has been made somewhat easier during the last several years by the development and clinical characterization of immunohistochemical panels. 3 n equally problematic diagnostic dilemma is the differentiation of a malignant mesothelial process from a reactive one. Reactive mesothelial proliferations may show high cellularity, cytologic atypia, necrosis, papillary excrescences, and entrapment ( pseudoinvasion ; benign mesothelial cells entrapped within organizing pleuritis). Conversely, malignant mesotheliomas may appear bland. ncillary studies are of little to no value in this scenario, and the distinction remains a clinicopathologic one, wherein the pathologic parameter is morphologic assessment by standard H&E light microscopy. 4 Osteopontin is a phosphoprotein with a variety of physiologic roles, including anchoring osteoclasts to bone mineral matrix, functioning as a normal component of elastic fibers of skin and aorta, and acting as a protein ligand of CD It has also been shown to be expressed in a variety of carcinomas, including lung, breast, and prostate recent study showed that patients with pleural malignant mesotheliomas 580 m J Clin Pathol 2007;127: DOI: /ME4VG11LDX8KMTN

2 natomic Pathology / ORIGINL RTICLE had significantly higher osteopontin levels than those in a noncancer group with a history of asbestos exposure. Expression of osteopontin in pleural malignant mesotheliomas in this cohort was demonstrated by immunohistochemical staining, and lung parenchyma and adjacent normal pleura were reportedly negative. 22 Given the recent findings linking increased serum osteopontin levels and malignant mesothelioma, we sought to determine if immunohistochemical osteopontin expression is diagnostically useful in distinguishing epithelioid mesothelioma from reactive mesothelial proliferations in recent material from our department s case file. Differential expression would suggest that immunohistochemical analysis using the osteopontin antibody may be a useful ancillary study when the distinction is difficult by histomorphologic examination alone. Materials and Methods pproval for this research was granted by our local institutional review board. total of 7 cases of epithelioid mesothelioma (2 autopsy cases, 5 surgical biopsy and resection specimens) and 20 cases of reactive or atypical mesothelial proliferations were studied. These cases were extracted from our departmental files using a retrospective SNOMED (Systematic Nomenclature of Medicine) terminology search in our laboratory information system (CERNER, Kansas City, MO). The diagnostic H&E-stained slides were reviewed from each case, and clinical follow-up was obtained in the cases of reactive or atypical mesothelial processes to ensure that none of the patients developed malignancy of the pleura up to the time of this study. Immunohistochemical studies were also reviewed for accuracy of interpretation in the cases of mesothelioma. Immunohistochemical analysis was subsequently performed on formalin-fixed, paraffin-embedded tissue sections with antiosteopontin antibody (mouse, monoclonal, clone Km21, Santa Cruz iotechnology, Santa Cruz, C). citrate buffer microwave pretreatment was performed on unstained paraffin sections, and osteopontin antibody was applied at a 1:100 dilution using the DKO utostainer (DKO, Carpinteria, C). The detection system used was the DKO EnVision Plus Polymer System. The chromogen used was D Plus (DakoCytomation, Carpinteria, C). n epithelioid mesothelioma demonstrating robust staining with the osteopontin antibody was selected as a positive control sample for all runs, and negative control experiments were performed appropriately. Expression of osteopontin in malignant and reactive mesothelial cells was evaluated independently by 2 pathologists (D.T. and J..W.) using a semiquantitative scale denoting the extent of staining (percentage of the cells of interest that stain with osteopontin antibody). The scoring system applied was as follows: 0, no cells staining; 1, fewer than 25% of cells staining; 2, 25% to 50% of cells staining; and 3+, more than 50% of cells staining. For discrepancies, the cases were reexamined at a 2-headed scope, and the staining score was reached by consensus. Results The individual scoring of osteopontin expression and patient age and sex data are listed in Table 1. ll 7 mesotheliomas and 19 of 20 reactive mesothelial proliferations showed cytoplasmic osteopontin expression Table 2. Positive osteopontin staining was observed in a granular cytoplasmic pattern without membrane or Golgi accentuation. Nuclear staining was not observed. staining distribution of 2+ or greater was demonstrated by 7 (100%) of 7 mesotheliomas and 13 (65%) of 20 reactive mesothelial proliferations Table 3. In general, the intensity of the expression was subjectively greater in the malignant mesothelioma group Image 1 than in the reactive mesothelial group Image 2 and Image 3. Table 1 Clinical Data and Osteopontin Expression Scores * Case No./Sex/ge (y) Date of Procedure Score Mesothelioma cases 1/F/55 July 11, /M/74 March 29, /F/52 January 25, /M/66 February 3, /M/74 December 14, /M/78 January 6, /M/78 February 3, Reactive mesothelium cases 1/M/70 February 25, /M/82 September 19, /M/48 October 3, /M/78 November 26, /F/59 January 27, /F/36 October 3, /M/22 September 13, /M/16 pril 12, /M/23 October 19, /F/50 July 30, /M/20 January 11, /M/21 December 19, /M/25 December 27, /M/60 December 23, /F/14 June 20, /M/68 June 8, /M/60 December 23, /M/44 pril 26, /F/18 pril 11, /M/85 May 19, * The osteopontin scoring system was as follows: 0, no cells staining; 1+, <25% of cells staining; 2+, 25%-50% of cells staining; 3+, >50% of cells staining. Mean age, 68.1 years; men, 71%. Mean age, 45.0 years; males, 75%. m J Clin Pathol 2007;127: DOI: /ME4VG11LDX8KMTN 581

Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital

Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix

Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are

Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: 10.1309/6A30YQHBMTHEJTEM It has been evident for decades that pathology reports

Uses and Abuses of Pathology in Asbestos-exposed Populations Jerrold L. Abraham, MD Department of Pathology State University of New York Upstate Medical University Syracuse, NY, 13210 USA The term: Asbestosis,

Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred

Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland

PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of

3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which

NONGYNECOLOGIC CYTOPTHOLOGY CK5/6 in Effusions No Difference etween Mesothelioma and Pulmonary and Nonpulmonary denocarcinoma nnika Dejmek, M.D., Ph.D. Objective To test the performance of CK5/6 for the

A Gene Expression Test to Predict Prostate Cancer Aggressiveness Use Prolaris as a guide in your medical and surgical management What is Prolaris? A direct molecular measure of prostate cancer tumor biology

Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent

Dr. Anthony C.H. YING What are? Tumour markers are substances that can be found in the body when cancer is present. They are usually found in the blood or urine. They can be products of cancer cells or

For media outside the US, UK and Canada only P L E U R A L M E S O T H E L I O M A 1. Overview 2. What is pleural mesothelioma? 3. How common is pleural mesothelioma? 4. What are the risk factors for pleural

Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Protocol revision date: January 2004 No AJCC/UICC staging system

Anatomic Pathology / MIB-1 AND MCM-2 AND SERRATED POLYPS MIB-1 and MCM-2 Immunohistochemical Analysis Does Not Aid in Identification of Serrated Colorectal Polyps With Abnormal Proliferation David Gray,

Cytological Diagnosis of Malignant Pleural Mesothelioma: A Cautionary Note for Lawyers in Asbestos Litigation Edward Casmere and Joshua Lee Law360 March 7, 2014 For a variety of reasons, lawyers in asbestos

UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7

Lung Carcinomas New 2015 WHO Classification Spasenija Savic Pathology ***EXPECTED SPRING 2015*** This authoritative, concise reference book provides an international standard for oncologists and pathologists

MALIGNANT MESOTHELIOMA: A TYPICAL PRESENTATION IN AN ATYPICAL PATIENT Written by: Karyn Varley MS, SCT(ASCP) The donating laboratory would like to remain anonymous. PATIENT HISTORY 28 year old female Lived

MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,

Advances in Treatment of Malignant Pleural Mesothelioma: A Reason for Hope Daniel H. Sterman, M.D. Associate Professor of Medicine and Surgery Co-Director, PENN Mesothelioma and Pleural Program University

Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy

Hello. My name is Ayse Sahin. I m a Professor of Pathology at University of Texas MD Anderson Cancer Center. I would like to review Pathology of Breast Cancer. Upon completion of this lecture, participants

Fact Sheet: Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the American Cancer Society, an estimated 1.48 million new

Angiosarcoma, Radiation-Associated Angiosarcoma, and Atypical Vascular Lesion N Angiosarcoma, one of the least common sarcomas, has become increasingly important because of its association with radiation

Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors and malignant mesothelial neoplasms of the